Laboratorios Farmacéuticos ROVI, S.A., headquartered in Madrid, Spain, has grown into a significant pharmaceutical company since its founding in 1946. Specializing in developing, manufacturing, and commercializing a wide range of medicines, ROVI is mainly known for its expertise in thrombosis treatments, exemplified by its flagship product, Bemiparin. The company operates globally, with subsidiaries in Germany, France, Italy, the UK, and Portugal, expanding its presence across Europe. In March 2024, ROVI reached a milestone with US FDA approval of Risvan® (Risperidone ISM®), a long-acting injectable for treating schizophrenia, marking its first US-approved product and demonstrating its innovation. ROVI also plays a vital role in contract development and manufacturing, producing drugs for leading pharmaceutical companies. With recent investments in expanding its manufacturing capacity, particularly in long-acting injectables, ROVI is well-positioned for continued development and growth in the global market.
You are here: Home / Investments / Growth Sectors / Innovative Healthcare Leaders / Laboratorios Farmacéuticos ROVI